Clinical trial
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To…
NCT00407745 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00407745 |
|---|---|
| Title | A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury |
| Official title | A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neuralgia, Spinal Cord Injuries |
| Intervention type | Drug |
| Interventions | placebo, pregabalin |
| Enrollment | 220 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Dec 5, 2006 |
| Last update posted | Jan 25, 2021 |
| Countries | Chile, China, Colombia, Czechia, Hong Kong, India, Japan, Philippines, Russia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: